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Abstract
Background: Francisella tularensis is a zoonotic intracellular bacterial pathogen that causes
tularemia. The subspecies tularensis is highly virulent and is classified as a category A agent of
biological warfare because of its low infectious dose by an aerosol route, and its ability to cause
severe disease. In macrophages F. tularensis exhibits a rather novel intracellular lifestyle; after
invasion it remains in a phagosome for three to six hours before escaping to, and replicating in the
cytoplasm. The molecular mechanisms that allow F. tularensis to invade and replicate within a host
cell have not been well defined.
Methods: We constructed a stable transposon mutagenesis library of virulent strain Schu S4 using
a derivative of the EZ::TN transposon system®. Approximately 2000 mutants were screened for
the inability to invade, and replicate in the hepatic carcinoma cell line HepG2. These mutants were
also tested for replication within the J774.1 macrophage-like cell line.
Results: Eighteen mutants defective in intracellular replication in HepG2 cells were identified. Eight
of these mutants were auxotrophs; seven had mutations in nucleotide biosynthesis pathways. The
remaining mutants had insertions in genes that were predicted to encode putative transporters,
enzymes involved in protein modification and turnover, and hypothetical proteins. A time course
of the intracellular growth of a pyrB mutant revealed that this mutant was only able to grow at low
levels within HepG2 cells but grew like wild-type bacteria in J774.1 cells. This pyrB mutant was also
attenuated in mice.
Conclusion: This is the first reported large-scale mutagenesis of a type A strain of F. tularensis and
the first identification of mutants specifically defective in intracellular growth in a hepatic cell line.
We have identified several genes and pathways that are key for the survival and growth of F.
tularensis in a hepatic cell line, and a number of novel intracellular growth-defective mutants that
have not been previously characterized in other pathogens. Further characterization of these
mutants will help provide a better understanding of the pathogenicity of F. tularensis, and may have
practical applications as targets for drugs or attenuated vaccines.
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Francisella tularensis is a gram-negative bacterium that
causes a potentially life-threatening disease called
tularemia [1]. There are several subspecies of Francisella
but F. tularensis tularensis and F. tularensis holarctica, also
known as Type A and Type B, respectively, are the most
prevalent. Type A isolates have been classified as a cate-
gory A select agent of biological warfare. They are typically
restricted to North America, and can cause a severe infec-
tion that is potentially fatal, particularly if untreated. Type
B isolates are found primarily in the Northern Hemi-
sphere, and cause a milder disease that is rarely fatal.
These bacteria are zoonotic organisms that can infect hun-
dreds of different species. F. tularensis is usually transmit-
ted to humans, an incidental host, by the bite of an
arthropod vector but it is also possible to become infected
through an aerosol route.
F. tularensis is a facultative intracellular bacterium that can
invade a variety of cell types including macrophages,
endothelial cells, and hepatocytes [2-4]. In macrophages
F. tularensis exhibits a rather unusual intracellular lifestyle.
Most intracellular bacteria reside and replicate within a
remodeled phagosome that is able to avoid lysosomal
fusion through a variety of mechanisms. Other bacteria
rapidly escape the phagosome after invasion and replicate
directly in the cytoplasm. Francisella seems to have com-
bined these two pathways; after uptake it remains in a
phagosome for three to six hours before escaping to, and
replicating in the cytosol [5-8]. A few factors have been
identified that regulate or facilitate phagosome escape and
intracellular survival of F. tularensis [9-12], but relatively
little is known about the molecular mechanisms or neces-
sary requirements of this intracellular lifestyle. To gain a
better understanding of the requirements for invasion,
phagosome escape, and intracellular replication and sur-
vival, we created a transposon mutagenesis library of the
type A strain Schu S4 using EZ::TN <rpsLpRparr-2>, a deriv-
ative of the EZ::TN transposon system® [13]. Schu S4 is a
human isolate, and its genome has been completely
sequenced [14]. Approximately 2000 mutants were
screened for the inability to replicate in the hepatic cell
line, HepG2. This cell line was chosen because mouse
studies of tularemia have indicated that the liver is the pri-
mary site of tularemia pathology, and intracellular bacte-
ria are visible in hepatocytes [15]. The range of mutants
isolated in this screen has identified some key aspects of
the requirements for intracellular survival in a hepatic cell
line. Further characterization of these mutants will help to
define the pathways, and processes that lead to successful
infection.
Results
Construction of a transposon-insertion library of Schu S4
We used the transposon EZ::TN<rpsLpRparr-2> to create a
transposon-insertion library of the F. tularensis type A
strain Schu S4 (Fig. 1). This transposon was previously
used to identify mutants in Rickettsia prowazekii and carries
the gene Rparr-2, which encodes an enzyme that inacti-
vates rifampin by ADP-ribosylation [13]. The transposon
was isolated from pMW1409 by restriction enzyme diges-
tion and gel electrophoresis. The purified transposon was
incubated with transposase, and then the "transposome"
complex was introduced into Schu S4 by electroporation.
Rifampin-resistant colonies were selected on MHA plates
containing rifampin. Approximately 10,000 rifampin-
resistance colonies were isolated, individually grown, and
frozen in 96 well microtiter plates. The presence of the
transposon in the rifampin-resistant colonies was verified
by PCR amplification of the transposon from DNA iso-
Map of transposon EZ::TN<rpsLp Rparr-2> that was used to create transposon-insertion library in Schu S4Figure 1
Map of transposon EZ::TN<rpsLp Rparr-2> that was used to create transposon-insertion library in Schu S4. 
Rparr-2 is a gene that encodes resistance to rifampin by inactivation of the drug. Arrows indicate the location of various prim-
ers that were used to for PCR amplification of the transposon or sequencing the flanking DNA. ME-mosaic ends (specifically 
recognized by the EZ::TN transposase), R6Kγori is an origin of replication that is used to rescue the transposon after it is 
inserted into the genome.Page 2 of 12
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BM007 and 3'arr-2 (data not shown). The transposition
frequency was approximately 2.0 × 10-5 per input colony
forming unit (CFU).
To examine the randomness of the transposition event the
transposon with its flanking DNA was rescued from 33
colonies by digesting the DNA with Bcl1, self-ligating the
fragments, and introducing them into pir+E. coli. The DNA
flanking the transposon was sequenced, and found to be
100% identical to Schu S4 sequences. The location of each
transposon insertion site on a chromosomal map of Schu
S4 is shown in Fig. 2. Two insertion sites appeared to be
in intergenic regions while the rest were within putative
open reading frames. The insertion sites were generally
spread around the chromosome with no major hotspots,
however there were three regions of significant size to
which no insertion sites mapped.
To test the stability of the transposition event ten mutants
were replated five times on MHA with or without
rifampin. In all cases rifampin resistance was stable. In
two strains the DNA flanking the transposon was
sequenced, and found to be identical to that of the origi-
nal rescued plasmid. These results indicated that the trans-
poson was stable once integrated into the Schu S4
genome.
Isolation of mutants defective in intracellular survival in 
HepG2 cells
To identify potential virulence factors, and also define
requirements for intracellular survival of Schu S4, the
transposon-insertion library was screened for mutants
Chromosomal location of transposon EZ::TN<rpsLp Rparr-2> in selected strains from the transposon-insertion library of Schu S4Figure 2
Chromosomal location of transposon EZ::TN<rpsLp Rparr-2> in selected strains from the transposon-insertion 
library of Schu S4. A circular map of the Schu S4 chromosome showing the location of transposon insertion sitesPage 3 of 12
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pendent mutants by incubating each mutant with HepG2
cells in a microtiter well. After two hours the cells were
washed, and gentamicin was added. After a 24 hr incuba-
tion the cells were lysed, and each lysate was transferred to
a MHA plate and further incubated for 48 hours (Fig. 3).
Strains that failed to grow on the MHA plate were retested
two more times. Twenty-seven mutants were finally iden-
tified that failed to replicate within HepG2 cells. The loca-
tion of the transposon insertion site in the Schu S4
genome for each mutant was determined (Table 2). Eight-
een different genes were identified from these 27 mutants.
In all cases the transposon inserted in orientation such
that the direction of transcription of the Rparr-2 gene was
the same as the disrupted open reading frame. This sug-
gests that the Rickettsia rpsL promoter was not active in
Schu S4, and that the expression of the Rparr-2 gene was
driven by the nearest upstream promoter. A Southern blot
of DNA isolated from 15 of these strains, and hybridized
with a probe specific for Rparr-2, demonstrated that each
mutant had a single integrated copy of EN::TN<rpsLpRparr-
2> (Fig. 4). Fifteen of the 18 genes disrupted by a transpo-
son had annotations for a predicted gene function (Table
2). Only three were designated as hypothetical. In several
of these mutants the transposon had inserted into a gene
that appeared to be part of an operon, therefore the defect
in intracellular survival in these mutants may be due to a
polar effect on downstream genes. Eight of the 18 mutants
were auxotrophs. Seven of these 8 auxotrophic mutants
had transposon insertions in genes involved in purine or
pyrimidine nucleotide biosynthesis.
Characterization of a mutant in the pyrimidine nucleotide 
biosynthesis pathway
The initial enzymes in the pyrimidine nucleotide biosyn-
thesis pathway appear to be encoded by a three-gene
operon consisting of carA, carB, and pyrB (Fig. 5). The
products of these genes are carbamoyl-phosphate syn-
thase (small and large subunit), and aspartate carbamoyl-
transferase. The phenotype of BJM1001 (pyrB) was
characterized in greater detail. B. abortus pyrB mutants are
defective in intracellular growth in macrophages though
these bacteria reside within phagosomes [16]. As
expected, BJM1001 required added uracil, and not
arginine for growth on minimal CDM (Fig. 6). The ability
of BJM1001 to invade and replicate in HepG2 was com-
pared to wild-type Schu S4 (Fig. 7). At three hours post
infection there were approximately one third fewer intra-
cellular CFUs of BJM1001 than Schu S4. At 24 hours the
number of CFUs of Schu S4 had increased more than
1000 fold while BJM1001 numbers increased approxi-
mately 50 fold. At 48 hours the number of Schu S4 bacte-
ria remained roughly constant and BJM1001 had again
about a 50-fold increase. At 72 hrs the number of Schu S4
had begun to decline, while BJM1001 continued to slowly
increase. In summary, the growth defect of BJM1001 in
HepG2 cells manifested early in infection, however the
bacteria continued to grow, albeit at low levels, for at least
72 hrs post-infection.
The ability of BJM1001 to invade and replicate in J774.1
cells, a murine macrophage-derived cell line, was also
examined. J774.1 cells were infected with bacteria at an
MOI to 50:1 in microtiter wells in triplicate. After 2 hrs the
media was replaced with media containing gentamicin.
The wells were lysed at 3, and 24 hrs, diluted, and spread
on MHA plates to determine the number of intracellular
CFUs. In contrast to HepG2 cells, intracellular growth of
BJM1001 in J774.1 cells was similar to Schu S4. At 3 and
24 hrs the number of CFUs recovered from BJM1001 and
Schu S4 infected cells was approximately the same. At 24
hrs the number of intracellular bacteria in both strains
had increased by about 3 logs. Although the same number
of host cells and MOI were initially used to infect HepG2
and J774.1 cells, the number of CFUs recovered from
J774.1 cells at 3 and 24 hrs was nearly 3 logs higher than
with HepG2 cells. The experiment with J774.1 cells could
not be continued past the 24 hour time point because the
J774.1 cells began to die. Several other mutants were
tested for intracellular growth in J774.1 cells (Table 3 and
data not shown). Among 11 mutants tested, BJM1005
(dsbB) and BJM1026 (hypothetical protein) were pro-
Identification of mutants defective in intracellular growth in H pG2 cellsFigure 3
Identification of mutants defective in intracellular 
growth in HepG2 cells. Individual transposon-insertion 
mutants were incubated with HepG2 cells for two hours, 
treated with gentamicin, incubated for an additional 24 hrs, 
then the HepG2 cells were lysed. The lysates were trans-
ferred to MHA plates with a 48-pin replicator and incubated 
for 48 hours. Representative mutants that showed no or 
reduced growth after 48 hrs are indicated by arrowheads.Page 4 of 12
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while two others, BJM1004 and BJM1025, were moder-
ately defective. The mutant strains that grew similarly to
Schu S4 in J774.1 cells were BJM1001, BJM1002,
BJM1003, BJM1012, BJM1015, BJM1018, and BJM1024.
These results suggest that the requirements for intracellu-
lar growth, or possibly the intracellular environment of F.
tularensis in these two cell lines are quite different.
To determine whether the delayed growth phenotype of
BJM1001 in HepG2 cells translated to attenuation in vivo,
mice were infected with approximately 200 or 2000 CFUs
of BJM1001 or Schu S4 by an intranasal route. All mice
infected with 2000 CFUs of Schu S4 died or were eutha-
nized on Day 4. All mice infected with 200 CFUs of Schu
S4 died or were euthanized on Day 5. Some attenuation
of BJM1001 was observed; three out of four mice chal-
lenged with 2000 CFUs of BJM1001 died on Day 6, which
was a two day delay compared to a similar inoculum of
Schu S4. Two out of four mice challenged with 200 CFUs
BJM1001 also died on Day 6. The three remaining mice
appeared healthy with normal activity until day 10, when
they were euthanized. By gross examination the livers of
the surviving mice appeared normal, however bacteria
were isolated from liver homogenates. These results sug-
gest that the ability to grow within HepG2 cells correlates
with in vivo virulence.
Discussion
F. tularensis is remarkable for its ability to infect an array
of mammals, arthropods, and even protozoa with an
infectious dose of 10 organisms or less [17]. To accom-
plish these feats, the bacterium must have devised effi-
cient means of infecting its host, and effective ways of
avoiding host defense mechanisms. A key component of
successful infection should rely at least in part on its abil-
ity to invade, survive, and replicate inside host cells. The
intracellular lifestyle of F. tularensis in macrophages repre-
sents a novel paradigm for intracellular survival. Once
inside a macrophage F. tularensis is able to escape from the
phagosome and replicate in the cytoplasm. Unlike other
cytosolic intracellular bacteria such as Shigella sp and Lis-
teria monocytogenes, which escape from their phagosomes
within minutes after entering host cells [18,19], Francisella
resides in phagosomes that acquire endosomal markers
such as early endosomal antigen (EEA) 1 and the late
endosomal markers (LAMP) 1 and 2, for three to six hrs
after infection before escaping into the cytoplasm [5-
8,20]. In this study we used a random mutagenesis
approach to identify genes in F. tularensis that contribute
Southern blot of transposon insertion mutants of Schu S4 that were defective in intracellular growth in HepG2 cellsFigur  4
Southern blot of transposon insertion mutants of Schu S4 that were defective in intracellular growth in HepG2 
cells. Chromosomal DNA from mutants digested with BclI was subjected Southern hybridization with a PCR product amplified 
from the EZ::TN<rpsLpRparr-2> DNA template. Lanes 1–15 contain DNA from rifampin-resistant mutants of Schu S4. Lane 16 
contains wild-type Schu S4 DNA and Lane 17 contains the probe DNA. Each mutant contains a single copy of the transposon.Page 5 of 12
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tion.
A stable transposon-mutagenesis library was constructed
in Schu S4, a virulent isolate of F. tularensis tularensis.
Nearly all of the transposon-insertion sites were located
within open reading frames. It therefore appears that an
upstream endogenous promoter drove the transcription
of the transposon-encoded rifampin-resistance gene
Rparr-2 in Schu S4. Therefore our library is not completely
comprehensive because mutations in genes that are
poorly expressed in our culture conditions would not
have been isolated. We screened our library for mutants
defective in intracellular survival in HepG2 cells. A hepatic
cell line was chosen because in the mouse tularemia
model, regardless of the route of infection, bacteria dis-
seminate to the liver [15]. The genes that were disrupted
in these mutants provide insights into the pathways and
processes that are required for intracellular replication
and survival of F. tularensis. We did not identify in our
screen any mutants in the 30 kb pathogenicity island in F.
tularensis that encodes several novel proteins including
IglA, IglC, PdpA and PdpB, which are required for intrac-
ellular replication and survival of F. novicida in macro-
phages [7,9]. This was not unexpected because this
pathogenicity island is duplicated in Schu S4. By chance
one of the randomly selected mutants, which was not
defective in intracellular growth, had a transposon
inserted in pdpA (see Fig. 2, insertion at nucleotide
1774.7).
Seven out of the eight auxotrophic mutants identified in
our screen had transposon insertions in genes involved in
purine or pyrimidine nucleotide biosynthesis. Intact
Predicted operon (5A) and simplified pyrimidine nucleotide synthesis pathway (5B) in F.tularensisFigure 5
Predicted operon (5A) and simplified pyrimidine nucleotide synthesis pathway (5B) in F. tularensis. The direction 
of transcription of the putative operon is from left to right.Page 6 of 12
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found to be important for the virulence of several other
intracellular bacteria that reside within phagosomes,
including Brucella abortus [21], Brucella suis [22], Salmo-
nella typhimurium [23], and Mycobacteria tuberculosis [24].
Purine prototrophy has also been shown to be important
for the intracellular survival and virulence of Shigella
flexneri, a bacterium that replicates in the cytoplasm [25].
In our study the pyrB mutant, BJM1001, was defective in
intracellular replication in HepG2 cells, though it was
able to continue to grow at reduced levels. BJM1001 was
also attenuated in mice, exhibiting a delayed time to death
when compared to Schu S4. Although this is a single
mutant, it suggests that the ability to replicate within
HepG2 cells may be useful as a correlative test for viru-
lence in vivo. This mutant showed no growth defects in
J774.1 cells. These results suggest that the availability or
accessibility of pyrimidines to the bacteria is different in
these two cell types. The intracellular fate of F. tularensis
has really only been examined carefully in macrophages
or macrophage cell lines, and not in hepatocytes or
hepatic cell lines. The time course of phagosomal escape
may be different in hepatic cells or may not even occur.
The differences in the ability of some of our mutants to
replicate in these two cell types may be a reflection of the
exposure of F. tularensis to different intracellular compart-
ments or environments, or some species-specific factors
since HepG2 cells are a human-derived cell line and
J774.1 have a murine origin.
Most intracellular gram-negative bacteria reside within a
phagosome, and have developed different mechanisms to
avoid fusion with lysosomes. The best-studied exceptions
are Shigella sp., which survive and replicate directly in the
cytoplasm. One explanation for this skew is that the cyto-
plasm is not a particularly hospitable environment for
bacterial growth and survival. Although the intracellular
fate of F. tularensis in hepatocytes has not been studied in
detail, two mutants obtained in our screen, dsbB and ggt,
disulfide bond formation protein B and gamma-glutamyl
transferase (GGT), respectively, suggest that F. tularensis is
in contact with the cytosol in hepatocytes, and may reflect
F. tularensis adaptation to living in the cytoplasm. The
cytosol is a reducing environment due to glutathione
reductase, and contains high levels of reduced glutath-
ione, which is necessary to inhibit protein folding in the
cytoplasm [25]. The periplasm of gram-negative bacteria
typically contain several disulfide bond formation pro-
teins that catalyze disulfide bond exchange and help to
maintain the balance of redox potential [26]. DsbA cata-
lyzes disulfide bond formation and DsbB oxidizes DsbA
back to its active oxidized form. A functional DsbB
appears to be critical for F. tularensis intracellular growth
because this mutant exhibited one of the most severe
Uracil auxotrophy of pyrB mutant BJM1001Figure 6
Uracil auxotrophy of pyrB mutant BJM1001. Schu S4 mutant BJM1001 with transposon insertion in pyrB was spotted on 
CDM minimal media, containing supplements as indicated, and grown for 72 hours.Page 7 of 12
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cells.
DsbA has been identified as a virulence-associated gene in
several other pathogens [27]. DsbA also has a role in the
formation of pili. It is required for biogenesis of the type
IV pili of the Vibrio cholerae toxin-coregulated pilus and
the bundle forming pilus of enteropathogenic E. coli [28].
Genes that could encode a type IV pili are found within
the genome of Schu S4 [14,29]. A role for type IV pili in
invasion or intracellular survival has not been defined but
a knockout mutant in a potential pilin-encoding gene in a
type B isolate is attenuated by a subcutaneous route in
mice, and is impaired in its ability to spread to the spleen
[30].
Another potential adaptation to survival in the reducing
cytosol could be the activity of GGT. This enzyme has a
major role in glutathione metabolism [31]. GGT is the
first enzyme in the degradation pathway of glutathione,
and transfers a gamma-glutamyl moiety from glutathione
to amino acids. GGT can also use gamma-glutamyl pep-
tides as substrates in the reciprocal hydrolysis reaction,
thus contributing to the synthesis of glutathione. GGT in
Francisella may also help to control the influx of glutath-
ione from the cytosol. Further studies on these mutants
will help define the roles of these gene products in intrac-
ellular survival.
Conclusion
This is the first reported large-scale mutagenesis and
screening of a type A strain of F. tularensis. We have iden-
tified several genes and pathways that are key for the sur-
vival, and growth of a type A strain of F. tularensis in a
hepatic cell line. Conlan et al have shown in a mouse
model of tularemia that, regardless of the route of entry,
the liver appears to be a primary site of pathology, and
intracellular bacteria are visible in hepatocytes [15].
Defects in the growth of mutants in pyrimidine and
purine biosynthesis pathways suggest that these pathways
are important for optimal intracellular growth, but the
slow growth of the pyrB mutant inside HepG2 cells and in
vivo indicates that the bacteria must be able to procure
some nucleobases from the host. Several mutants defec-
tive in HepG2 intracellular growth were able to grow sim-
ilarly to wild-type bacteria in a murine macrophage-
derived cell line, suggesting that the intracellular environ-
ment, resources, and/or compartment available to the
bacteria in these two cells types are different. However, the
identification of dsbB and ggt mutants suggests that F. tula-
rensis is in contact with the cytosol in HepG2 cells. We also
identified a number of novel intracellular growth-defec-
tive mutants that have not been previously characterized
in other pathogens. Further characterization of these
mutants will provide a better understanding of the patho-
genicity of F. tularensis, and may have practical applica-
tions as attenuated vaccines or through the identification
of targets for new therapeutics.
Methods
Bacterial strains, and growth conditions
F. tularensis subsp. tularensis Schu S4 was obtained from
the Centers for Disease Control, Fort Collins, CO. Schu S4
was grown either on supplemented Muller-Hinton agar
(MHA) (Muller-Hinton Broth 21 g/L, Sodium Chloride 5
g/L, protease peptone 10 g/L, Bacto -Agar 16 g/L) or in
enriched Trypticase Soy Broth (TSB). Each medium was
supplemented with (wt/vol) 0.1% cysteine, 0.1% glucose,
0.25% ferric pyrophosphate and 2.5% horse serum (vol/
vol). Rifampin-resistant mutants were grown in the same
media but supplied with 25 μg/ml rifampin. Rifampin is
not used in the clinical treatment of tularemia. Permission
to construct rifampin-resistant forms of Schu S4 was
obtained from the CDC. To test for auxotrophic growth,
bacteria were grown in Chamberlain's defined medium
(CDM) [32] with or without arginine, and/or uracil at 200
μg/ml. All cultures were inoculated from frozen aliquots
of the initial stock, and subcultured no more than three
times. The LD50 of Schu S4 stock in C57/BL6 mice by
intranasal, and intraperitoneal routes was 10–100 bacte-
ria. All mice died within 4 to 5 days. All work with Schu
Invasion and intracellular survival of BJM1001 and Schu S4 in HepG2 cellsFigure 7
Invasion and intracellular survival of BJM1001 and 
Schu S4 in HepG2 cells. HepG2 cells were infected with 
BJM1001 at an MOI to 50:1 in microtiter wells. After 2 hrs 
the media was replaced with media containing gentamicin. 
Sets of three wells were lysed at 3, 8, 24, 48 and 72 hrs, 
diluted, and spread on MHA plates to determine the number 
of intracellular colony forming units (CFUs). Each time point 
represents the average and standard deviation (S.D.) of three 
wells.Page 8 of 12
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E. coli TransforMax EC100D pir-116 (F- mcrA D mrr-
hsdRMS-mcrBC) W80d lacZDM15 D lacX74 recA1 endA1
araD139 D (ara, leu) 7697 galU galK l- rpsL nulG pir-166
(DHFR) was purchased from Epicentre (Madison, WI)
[33]. E. coli was grown in Luria-Bertani (LB) agar or broth,
and when appropriate, ampicillin and rifampin were
added to final concentrations of 100 μg/ml and 50 μl/ml,
respectively.
Tissue culture cell lines and growth conditions
Human hepatocellular carcinoma cell line HepG2
(ATCC# HB-8065) and murine macrophage cell J774A.1
(ATCC# TIB-67) were grown in low glucose Gibco™ Dul-
becco's Modified Eagle Medium (DMEM) or in high glu-
cose DMEM, respectively, and supplemented with 10%
FBS. A 96-well plate was seeded with 20,000 cells per well,
and grown at 37°C, 5% CO2 overnight before infection
with Schu S4-derived mutant strains.
Transposon library construction
The transposon-containing plasmid, pMW1409, was
obtained from David Wood, University of South Ala-
bama. The transposon, EZ::TN<rpsLpRparr-2>, was pre-
pared as described by Qin et al [13]. Briefly, pMW1409
was digested with PvuII, and the fragment containing the
transposon was purified by gel electrophoresis and extrac-
tion. One μl of the transposon (120 ng/ml) was mixed
with 2 μl transposase, purchased from Epicentre® (1 U/
ml) and 1 μl glycerol. This "transposome" mixture was
incubated at 37°C for 30 min, room temperature for 30
min, then 4°C overnight. Competent F. tularensis Schu S4
bacteria were prepared based on the method described in
[34]. Briefly, a fresh culture of Schu S4 was spread on an
MHA plate, and incubated at 37°C, 5% CO2 overnight.
The bacterial lawn was harvested into ice-cold 0.2 M
sucrose, washed 4 times, then aliquoted (~5 × 108 bacte-
ria/50 μl per tube). One μl of the transposome mixture
was mixed with 50 μl of competent Schu S4, incubated on
ice for 10 minutes then transferred into 0.1-cm-gap elec-
troporation cuvette. The electroporation conditions were
2.5kV, 25uF, and 200 Ohms. After electroporation the
cells were plated on a warmed MHA plate, and incubated
for 37°C for 6 hrs. The bacterial lawn was collected into
1.6 ml TSB/C. Aliquots of 100 μl were spread on MHA
with 25 μg/ml rifampin, and incubated at 37°C, 5%CO2
for 48 hrs. Single colonies were inoculated into 96 well
microtiter plates containing 150 μl TSB/C with 25 μg/ml
rifampin. The plates were incubated at 37°C for 48 hrs.
Glycerol was then added to a final concentration of
12.5%. The plates were stored at -80°C.
To verify that EZ::TN<rpsLpRparr-2> was present in a
rifampin-resistant colony, a portion of the transposon was
amplified by PCR from chromosomal DNA using primers
that annealed to transposon mosaic ends (ME) (Fig. 1)
and to the 3' of Rparr-2 gene (Table 1).
DNA manipulation, PCR and sequencing
Bacterial chromosomal DNA was isolated using the Pure-
gene® DNA purification kit (Gentra systems, Inc., Minne-
apolis MN). Plasmid DNA was purified using the QIA
prep kit (Qiagen, Valencia, CA). PCR products and DNA
restriction fragments were isolated by gel electrophoresis,
and purified with the QIA quick gel extraction kit (Qia-
gen, Valencia, CA).
Determination of the transposon insertion locations
Identification of the transposon insertion sites was
accomplished by rescue cloning, or direct sequencing of
bacterial genomic DNA using primers BM008 or BM009
(Table 1) as described in [13] and [35]. Briefly for rescue
cloning, 4 μg of chromosomal DNA, isolated from each
rifampin-resistant mutant, was digested with Bcl1 and
self-ligated. The self-ligated plasmids were introduced
into E. coli TransforMax EC100D pir-116 by electropora-
tion. Transformants were selected on LB-rifampin plates.
The sequence of the DNA flanking the transposon on the
rescued plasmids was determined using primers SqFP or
SqRp (Table 1, Epicentre) at the DNA Sequencing facility
at the University of Virginia. The identity of the disrupted
gene was determined by comparing the sequence to the
Schu S4 genomic sequence deposited on the NCBI web-
site.
Table 1: Oligonucleotides used in this study
Name Sequence (5'-3') Source
SqFP GCCAACGACTACGCACTAGCCAAC Epicentre
SqRP GAGCCAATATGCGAGAACACCCGAGAA Epicentre
5'RParr-2 TAAGGAGGTATCATATGGTAAAAG D. Wood1
3'RParr-2 GTCTAGAGGATCCTTAATCTTC D. Wood1
BM007 GTTGGCTAGTGCGTAGTCGTTGGC This study
BM008 GTTGGCTAGTGCGTAGTCGTTGGC This study
BM009 CGTTAAACATGAGAGCTTAGTACG This studyPage 9 of 12
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Two to four μg of bacterial chromosomal DNA was
digested with BclI, separated on an 0.8% agarose gel,
transferred to nylon membrane, and denatured by stand-
ard procedures [36]. The probe used for hybridization was
synthesized by PCR using primers 5'arr-2 and 3'arr-2,
which anneal to the Rparr-2 gene of pMW1409
EZ::TN<rpsLpRparr-2> [13]. The probe was labeled with
DIG-dUTP using a kit according to the manufacturer's
instructions (Roche, Indianapolis, IN). Hybridization was
Table 3: Invasion and intracellular survival of selected Schu S4 mutants in J774.11
Strain No. of intracellular CFUs recovered from cells at 24 hrs.
SCHU S4 3.00 × 107 ± 0.346
BJM1025 (hflB) 1.80 × 107 ± 0.200 p < 0.0065*
BJM1004 (MFS) 1.35 × 107 ± 0.0866 p < 0.0013*
BJM1005 (dsbB) 8.33 × 105 ± 0.0577
BJM1026 (hypothetical) 2.32 × 105 ± 1.29
BJM1001 (pyrB) 1.80 × 108 ± 0.0643
BJM1002 (aroA) 2.18 × 108 ± 0.387
BJM1003 (yfiO) 1.17 × 108 ± 0.135
BJM10012 (carA) 1.14 × 108 ± 0.867
BJM10015 (purL) 4.03 × 107 ± 0.802
BJM10018 (purH) 2.70 × 107 ± 0.100
BJM1024 (Na+/H+ transporter) 1.12 × 108 ± 0.872
1J774.1 cells were infected with bacteria at an MOI to 50:1 After 2 hrs the media was replaced with media containing gentamicin. Sets of three wells 
were lysed 24 hrs later, diluted, and spread on MHA plates to determine the number of intracellular colony forming units (CFUs). Each time point 
represents the average of three wells.
* Compared to Schu S4
Table 2: Genes essential for intracellular growth of F.tularensis SCHU S4 in Hep G2 cells
Strain Name Locus tag1/Genbank protein 
Accession # (*)
Gene Name (putative function)
Nucleotide metabolism
BJM1011 FTT1663/YP_170570 carA (carbamoyl-phosphate synthase small chain)
BJM1012 FTT1664/YP_170571.1 carB (carbamoyl-phosphate synthase large chain)
BJM1001 FTT1665/YP_170572.1 (2X) pyrB (aspartate carbamoyltransferase)
BJM1014 FTT0204/YP_169264.1 purA (adenylosuccinate synthetase)
BJM1015 FTT1720c/YP_170622.1 (3X) purL (phosphoribosylformylglycinamidine synthase)
BJM1018 FTT0203c/YP_169263.1 (3X) purH (bifunctional purine biosynthesis protein)
BJM1020 FTT1721c/YP_170623.1 (2X) purF (amidophosphoribosyltransferase)2
Amino acid transport and metabolism
BJM1002 FTT0588/YP_169611.1 aroA (3-phosphoshikimate 1-carboxyvinyl transferase)
BJM1021 FTT1181c/YP_170144.1 ggt (gamma-glutamyl transpeptidase)
General function prediction
BJM1003 FTT1244c/YP_170202.1 yfiO (conserved hypothetical lipoprotein)
BJM1022 FTT0129/YP_169196.1 major facilitator super family (MFS) transport protein
BJM1004 FTT0056c/YP_169131.1 major facilitator super family (MFS) transport protein
Inorganic ion transport metabolism
BJM1024 FTT1490/YP_170425.1 Na+/H+ antiporter
Cell wall/membrane biogenesis
BJM1023 FTT1234/YP_170192.1 choloylglycine hydrolase family protein
BJM1026 FTT1236/YP_170192.1 hypothetical protein
BJM1028 FTT1103/YP_170079.1 conserved hypothetical lipoprotein
Lipid metabolism
BJM1013 FTT1762c/YP_170653.1 acetyltransferase protein
Posttranslational modification/protein turnover
BJM1025 FTT1310c/YP_170263.1 hflB (ATP-dependent metalloprotease)
BJM1005 FTT0107c/YP_169177.1 (3X) dsbB (disulfide bond formation protein)
1Locus tag: http://biocyc.org/FRANT/
2This mutant was previously identified in F. tularensis novicida .
(*) Number of times a mutant in this ORF was isolated [11].Page 10 of 12
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(Roche, Indianapolis, IN). After hybridization, the mem-
brane was washed twice for 5 min in 2 × SSC, 1% SDS at
room temperature, twice for 15 min in 0.1% SSC, 0.1%
SDS at 68°C and once in 0.1% SSC for 5 min at room tem-
perature. Probe hybridization was detected using the pro-
tocol of the ECL western blotting detection kit
(Amersham, Piscataway, NJ) with anti-DIG-POD as the
secondary antibody (Roche, Indianapolis, IN).
Library screening
The protocol for screening the library was based on the
method described by Kawula et al [35]. A duplicate of a
stored microtiter plate was created by inoculating 20 μl
into a new 96 well plate containing 150 μl TSB/C in each
well. This plate was incubated at 37°C, 5% CO2, for 48
hrs, which resulted in 0.3 to 0.5 OD595 of bacteria in each
well. Five μl of the culture was added into another 96 well
plate in which 20,000 HepG2 cells per well had been
seeded 12 hrs earlier. The multiplicity of infection (MOI)
ranged from around 75 to 125 bacteria to 1 host cell.
These plates were centrifuged at 1000 × g for 8 min. After
incubation at 37°C, 5% CO2, for 2 hrs, fresh media with
gentamicin was added to a final concentration of 50 μg/
ml. The plates were incubated at 37°C, 5% CO2 for 24 hrs.
After incubation the media was discarded and the cells
were lysed by the addition of 150 μl TSB/C containing
0.1% sodium deoxycholate for 5 min at 37°C. Each lysate
was transferred to a MHA plate with a 48-pin replicator
and incubated for 48 hrs.
Invasion and intracellular replication assay
HepG2 or J774A.1 cells were seeded into 24 well plates (2
× 105 cell/well) and incubated at 37°C, 5% CO2, for 12
hrs. Before the addition of bacteria, the actually number
of HepG2 cells per well was determined by releasing the
cells with trypsin from three wells of the 24 well-plate and
calculating the number of cells in each well. Bacteria were
added at an MOI of 50:1. The plate was centrifuged at
1000 × g for 8 min and then incubated for 1 hr at 37°C,
5% CO2. Fresh media containing 50 μg/ml gentamicin
was then added. For invasion assays plates were incubated
for 1 hr at 37°C, 5% CO2; for intracellular replication
assays they were incubated for 2–72 hrs. At the end of the
incubation time the wells were lysed by the addition of
sodium deoxycholate to a final concentration of 0.1% in
TSB/C. The number of bacteria was determined by plating
dilutions of the lysates on MHA plates. These intracellular
growth assays were repeated at least three times.
Mouse infections
Six to eight week old C57BL/6 mice (Jackson Labs, Bar
Harbor, ME) were lightly anesthetized, and then inocu-
lated with bacteria in a volume of 20 μl by an intranasal
route. Bacteria were grown overnight in TSB/c broth to a
density of 1 × 109 CFU/ml, and stored in aliquots at -
80°C. For inoculation the bacteria were thawed and
diluted in sterile saline. The number of bacteria in an
inoculum was verified by plating on cysteine heart agar
plates supplemented with horse serum. All animals were
monitored daily for morbidity and mortality. Animals
were euthanized under anesthesia when signs of irreversi-
ble mortality were evident.
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